Pattern of Postoperative Recurrence and Hepatic and/or Pulmonary Resection for Liver and/or Lung Metastases From Esophageal Carcinoma

Ishikawa, Hirofumi; Imamura, Hiroshi; Yoshimoto, Jiro; Sugo, Hiroyuki; Kajiyama, Yoshiaki; Takahashi, Masahīko; Suzuki, Kenji; Ishizaki, Yoichi; Kawasaki, Seiji

doi:10.1007/s00268-012-1830-7

Cited by 71 publications

(67 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, two of the four patients remain disease free at 22 and 92 months, and in this group, particularly patient 2 who had unfavorable hepatic pathology, a survival advantage may have been offered by liver resection, although this cannot be proven from the present report. Our findings are comparable to the results of Ichida et al . who report five patients who underwent hepatectomy for esophageal liver metastases from their institution in Japan.…”

Section: Discussionsupporting

confidence: 91%

“…In their recent article, Ichida et al . postulate that although liver metastases are indicative of hematogenous metastases, hepatectomy may still offer curative treatment in those with a favorable tumor biology.…”

Section: Discussionmentioning

confidence: 99%

“…In their recent article, Ichida et al 19 postulate that although liver metastases are indicative of hematogenous metastases, hepatectomy may still offer curative treatment in those with a favorable tumor biology. Appreciation of tumor biology is crucial and may be predicted through the number of metastases and a long disease-free interval prior to developing liver metastases.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Liver metastases from esophageal carcinoma: is there a role for surgical resection?

et al. 2014

View full text Add to dashboard Cite

Esophageal cancer recurrence rates after esophagectomy are high, and locally recurrent or distant metastatic disease has poor prognosis. Management is limited to palliative chemotherapy and symptomatic interventions. We report our experience of four patients who have undergone successful liver resection for metastases from esophageal cancer. All underwent esophagectomy and were referred to our unit with metastatic recurrent liver disease, two with solitary metastases and two with multi-focal disease. The patients underwent multidisciplinary assessment and proceeded to a course of neoadjuvant chemotherapy followed by open or laparoscopic liver resection. Three patients were male, and the mean age was 57.5 (range 44-71) years. Response to chemotherapy ranged from partial to complete response. Following liver resection, two patients developed recurrent disease at 5 and 15 months, and both had disease-specific mortality at 10 and 21 months, respectively. The other two patients remain disease free at 22 and 92 months. Recurrent metastatic esophageal cancer continues to have a poor prognosis, and the majority of patients with liver involvement will not be candidates for hepatic resection. However, this series suggests that in selected patients, liver resection of metastases from esophageal cancer combined with neoadjuvant and adjuvant chemotherapy is feasible, but further research is required to determine whether this can offer a survival advantage.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Liver metastases from esophageal carcinoma: is there a role for surgical resection?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Results: A univariate analysis showed that distant organ recurrence, the number of recurrent tumors, the longest diameter of the largest recurrent tumor, the sum of all of the longest diameters of the recurrent tumors, invasion into adjacent structures and the speed of growth of the representative recurrent tumors were significantly associated with the post-recurrence prognosis. A multivariate analysis showed that distant organ recurrence, the longest diameter of the largest recurrent tumor, invasion into adjacent structures and the speed of growth of the representative recurrent tumors were significantly associated prognosis [5][6][7] . Therefore, the circumstances regarding postoperative recurrence are changing, and aggressive multimodality treatments for recurrence have been developed to improve the post-recurrence prognosis [8] .…”

Section: Introductionmentioning

confidence: 99%

Prognostic Factors for Post-Recurrence Survival in Patients with Thoracic Esophageal Squamous Cell Carcinoma after Curative Resection

Nakajima

Kawada²,

Tokairin³

et al. 2016

Dig Surg

View full text Add to dashboard Cite

Background/Aims: We investigated factors affecting the post-recurrence prognosis in order to develop adequate therapeutic guidelines for determining the indication for treatment of recurrent esophageal squamous cell carcinoma (ESCC). Methods: Ninety-three thoracic ESCC patients who developed postoperative recurrence after undergoing curative esophagectomy with 3-field lymphadenectomy at our institute and who received treatment for recurrence were enrolled in this study. Results: A univariate analysis showed that distant organ recurrence, the number of recurrent tumors, the longest diameter of the largest recurrent tumor, the sum of all of the longest diameters of the recurrent tumors, invasion into adjacent structures and the speed of growth of the representative recurrent tumors were significantly associated with the post-recurrence prognosis. A multivariate analysis showed that distant organ recurrence, the longest diameter of the largest recurrent tumor, invasion into adjacent structures and the speed of growth of the representative recurrent tumors were significantly associated with the prognosis. The patients whose recurrent tumor(s) did not meet all 4 of these factors showed a better prognosis. In contrast, the prognosis of the patients whose recurrent tumor(s) demonstrated all 4 factors was almost the same as that observed in the patients who did not receive any treatment for recurrence. Conclusions: The evaluation of these 4 factors may potentially be used to determine the indication for treatment for recurrence.

show abstract

“…For recurrence of distant metastasis alone, a reasonable OS was also attained in the present study. If curative resection could be possible, surgery could be considered a curative option for distant metastasis, as recently proposed in esophageal cancer [26,27] . These findings suggest the novel notion that recurrences after NAC could be managed for cure by optimal multimodality treatments.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence

Yamashita¹,

Hosoda²,

Moriya³

et al. 2017

Oncology

View full text Add to dashboard Cite

Background: Neoadjuvant chemotherapy (NAC) has become prevalent in esophageal squamous cell carcinoma (ESCC), but its long-term prognostic advantages remain unclear. The latest prognostic outcomes in clinical Stage (cStage) II/III ESCC with NAC were herein elucidated. Patients and Methods: NAC prior to curative treatment was done in 115 cStage II/III ESCC patients with either cisplatin (CDDP)/5-fluorouracil (5-FU; CF) (n = 41) or docetaxel/CDDP/5-FU (DCF) NAC (n = 74) between 2007 and 2013. Results: (1) Esophagectomy was finally performed in 35 of the 41 CF NAC cases and in 48 of the 74 DCF NAC cases. The preservation rate of the esophagus was higher in the DCF NAC than in the CF NAC (p = 0.018). (2) The overall survival was better in DCF NAC than in CF NAC (p = 0.071), and progression-free survivals were 58.3% with DCF and 30.5% with CF (p = 0.0060). DCF NAC was associated with fewer cases of progression than CF NAC (p = 0.0040), largely due to excellent control of the preoperative disease (p = 0.018) and postoperative lymph node recurrence (p = 0.014). Conclusion: DCF NAC in cStage II/III ESCC could have a great potential to achieve a better prognosis due to suppression of specific progression events with a higher preservation rate of the esophagus.

show abstract

Pattern of Postoperative Recurrence and Hepatic and/or Pulmonary Resection for Liver and/or Lung Metastases From Esophageal Carcinoma

Abstract: Resection of pulmonary metastases yields a survival benefit in properly selected patients. The benefit of resection for hepatic metastases remains controversial.

Cited by 71 publications

References 34 publications

Liver metastases from esophageal carcinoma: is there a role for surgical resection?

Liver metastases from esophageal carcinoma: is there a role for surgical resection?

Prognostic Factors for Post-Recurrence Survival in Patients with Thoracic Esophageal Squamous Cell Carcinoma after Curative Resection

Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence

Contact Info

Product

Resources

About